Selinexor

Selinexor has been studied in 4 papers since 2025: none in people yet, 2 in animals, 2 in cells; 3 in the past year. The research so far is in animals and cells. The newest paper, Nov 3, 2026: “Selinexor, a CRM1 inhibitor with anti-senescence activity, modulates the non- coding transcriptome of Hutchinson–Gilford progeria syndrome fibroblasts”.

InterventionApproved 2019

4 papers study it8 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 4 papers on selinexor

At a glance

The findings reach mice, none yet in people. 2 independent labs in 2 countries; 167 trials, none about aging, 28 with no results posted.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 2 independent labs in 2 countries
  • 167 trials, none about aging, 28 with no results posted
  • Funders: Karyopharm Therapeutics and others
  • 3 of 8 findings with company ties
  • 9 of 167 trials sponsored by its developers
  • Animals2
  • Cells2

What did studies of selinexor find?

7

Studies of selinexor measured 7 outcomes, among them autophagy, long noncoding RNA expression dysregulation and Progerin degradation.

Autophagy

upin human cells2

2 studies
  1. Selinexor activates autophagy in HGPS fibroblasts.

    “treatment of HGPS fibroblasts with Selinexor, an autophagy activator, elicited nuclear accumulation of TFEB and enhanced lysosomal biogenesis and function, thereby activating autophagy”

    Cellsin HGPS fibroblasts

    Progerin Hinders Autophagy Flux at Its Final Stages in Hutchinson-Gilford Progeria Syndrome Cells, Preventing Its Own Autophagic Degradation

    Aging cell

  2. Selinexor activates autophagy in HGPS fibroblasts.

    “treatment of HGPS fibroblasts with selinexor mitigated senescence and promoted progerin clearance via autophagy”

    Cellsin HGPS fibroblasts

    Targeting CRM1 for Progeria Syndrome Therapy

    Aging cell

More on Autophagy

Long noncoding RNA expression dysregulation

downin human cells1

1 study
  1. Selinexor decreases long noncoding RNA expression dysregulation in human cells (Hutchinson-Gilford progeria syndrome).

    “HGPS fibroblasts treated with selinexor, a CRM1-mediated nuclear export inhibitor with antisenescence activity, reversed missregulation of the lncRNA profile.”

    CellsHutchinson-Gilford progeria syndromefibroblast

    Selinexor, a CRM1 inhibitor with anti-senescence activity, modulates the non- coding transcriptome of Hutchinson–Gilford progeria syndrome fibroblasts

    Research SquarePreprint

Progerin degradation

upin human cells1

1 study
  1. Selinexor increases progerin degradation in HGPS fibroblasts.

    “Selinexor treatment improved both autophagosome maturation and autophagosome-lysosome fusion, which ultimately led to effective autophagic degradation of progerin”

    Cellsin HGPS fibroblasts

    Progerin Hinders Autophagy Flux at Its Final Stages in Hutchinson-Gilford Progeria Syndrome Cells, Preventing Its Own Autophagic Degradation

    Aging cell

age-associated inflammation

downin animals1

1 study
  1. Selinexor decreases age-associated inflammation.

    “Inhibition of XPO1 with KPT-330 suppresses nuclear R-loop export and its localization into CCFs, attenuates the SASP, mitigates age-associated inflammation and extends healthspan.”

    Animals

    Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging

    Nature aging

Senescence-associated secretory phenotype (SASP)

downin cells1

1 study
  1. Selinexor decreases senescence-associated secretory phenotype (SASP) in cells.

    “Inhibition of XPO1 with KPT-330 suppresses nuclear R-loop export and its localization into CCFs, attenuates the SASP”

    Cells

    Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging

    Nature aging

More on Senescence-associated secretory phenotype (SASP)

Aortic histopathology

downin mice1

1 study
  1. Selinexor decreases aortic histopathology in LmnaG609G/G609G mice.

    “oral administration of selinexor to the progeric mouse resulted in decreased progerin immunostaining in the liver and aorta, decreased progerin levels in most liver, lung and kidney samples analyzed by immunoblotting, and improved aortic histopathology”

    Animalsin LmnaG609G/G609G miceaorta

    Targeting CRM1 for Progeria Syndrome Therapy

    Aging cell

Cellular senescence

downin human cells1

1 study
  1. Selinexor decreases cellular senescence in HGPS fibroblasts.

    “treatment of HGPS fibroblasts with selinexor mitigated senescence and promoted progerin clearance via autophagy”

    Cellsin HGPS fibroblasts

    Targeting CRM1 for Progeria Syndrome Therapy

    Aging cell

More on Cellular senescence

Has selinexor been tested in people?

0 of 167 about aging

167 trials are registered, but no study of it in people has been published yet.

Approved

  • FDA Xpovio

    Jul 3, 2019Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • EMA Nexpovio

    Mar 26, 2021Multiple Myeloma

Repurposing

40 of 62

In trials

  • Lymphoma, large b-cell, diffuse

    Phase 4Status unknown10 trials

  • Leukemia myeloid acute

    Phase 3Status unknown22 trials

  • Neoplasm by site

    Phase 3Completed1 trial

  • Uterine disease

    Phase 3Completed1 trial

  • Lymphoma t cell peripheral

    Phase 2Terminated4 trials

  • Triple negative breast neoplasm

    Phase 2Results posted3 trials

All 30

Stopped

  • NCT01986348TerminatedGlioblastoma

    Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up)

  • NCT04843579TerminatedPlasma cell neoplasm

    low enrollment

  • NCT04854434TerminatedColorectal neoplasm

    Sponsor decision

  • NCT02314247TerminatedLymphoma t cell peripheral

    Due to enrollment challenges

  • NCT04768881TerminatedMelanoma

    The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab.

  • NCT02213133TerminatedCarcinoma

    Due to enrollment challenges and availability of other options for lung cancer patients. The termination is not a consequence of any safety concern.

All 14

Who is developing selinexor?

3 companies: Karyopharm Therapeutics, Qilu Pharmaceutical and US Oncology Research.

Companies
  • Karyopharm TherapeuticsPhase 3myelofibrosis, endometrial cancer
  • Qilu PharmaceuticalPhase 3relapsed or refractory multiple myeloma
  • US Oncology ResearchPhase 2multiple myeloma, myeloma multiple

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 13 papers in 12 months